People

BCI continues to seek high quality products with neurogenic profiles optimal for the treatment of mood disorders, psychoses, cognition, brain repair and other CNS disorders.

Since the importance of the role of neurogenesis in the treatment of CNS disease is relatively new, and BCI has established a robust and proprietary screening platform and related database, BCI believes that there are many opportunities to identify compounds addressing unmet CNS market needs. Future products can come from a variety sources:

• In-licensing clinical-stage compounds
• Screening qualified libraries to reposition clinical assets
• Identifying novel drug combinations which act synergistically
• In-house discovery programs